Alcon Drags Down Novartis’s Emerging Markets Performance
This article was originally published in PharmAsia News
Novartis's performance in emerging markets slowed in the third quarter, due mainly to a slowdown in Asia and the sluggish results of Alcon, which was hit by weaker surgical equipment sales in the sector. Alcon is aiming to turn things around with revitalized leadership and a growth acceleration plan.
You may also be interested in...
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.
Spectrum is set to discuss NDA submission plans with the US FDA after unveiling positive top line results from Cohort 2 of the Phase II ZENITH20 study with poziotinib, in pretreated NSCLC patients with HER2 exon 20 insertion mutations. The drug, licensed from Hanmi, failed in the Cohort 1 part of the trial earlier this year.